UroGen Pharma Ltd. (NASDAQ:URGN) Position Boosted by State Street Corp

State Street Corp increased its holdings in UroGen Pharma Ltd. (NASDAQ:URGN) by 5.9% during the third quarter, Holdings Channel reports. The firm owned 769,583 shares of the company’s stock after purchasing an additional 42,907 shares during the period. State Street Corp’s holdings in UroGen Pharma were worth $9,774,000 at the end of the most recent reporting period.

Several other institutional investors and hedge funds have also added to or reduced their stakes in the business. RTW Investments LP grew its position in UroGen Pharma by 6.5% in the third quarter. RTW Investments LP now owns 3,787,347 shares of the company’s stock worth $48,099,000 after buying an additional 230,000 shares during the last quarter. Parkman Healthcare Partners LLC boosted its stake in shares of UroGen Pharma by 26.6% during the 3rd quarter. Parkman Healthcare Partners LLC now owns 347,541 shares of the company’s stock worth $4,414,000 after acquiring an additional 73,076 shares in the last quarter. HighVista Strategies LLC acquired a new position in shares of UroGen Pharma in the 3rd quarter worth $490,000. Verition Fund Management LLC acquired a new stake in shares of UroGen Pharma during the third quarter worth $168,000. Finally, Vestal Point Capital LP purchased a new stake in shares of UroGen Pharma during the third quarter valued at $5,080,000. 91.29% of the stock is owned by institutional investors and hedge funds.

UroGen Pharma Trading Up 2.0 %

NASDAQ:URGN opened at $11.04 on Friday. The stock has a market cap of $258.93 million, a PE ratio of -3.50 and a beta of 1.06. UroGen Pharma Ltd. has a fifty-two week low of $10.26 and a fifty-two week high of $20.70. The company has a debt-to-equity ratio of 4.77, a current ratio of 9.00 and a quick ratio of 8.77. The stock’s 50-day moving average is $11.92 and its two-hundred day moving average is $13.76.

UroGen Pharma (NASDAQ:URGN) last posted its quarterly earnings results on Wednesday, November 6th. The company reported ($0.55) EPS for the quarter, topping the consensus estimate of ($0.84) by $0.29. The company had revenue of $25.20 million for the quarter, compared to analyst estimates of $24.22 million. During the same quarter in the prior year, the business posted ($0.68) earnings per share. As a group, equities research analysts forecast that UroGen Pharma Ltd. will post -3.1 earnings per share for the current fiscal year.

Wall Street Analysts Forecast Growth

A number of brokerages recently weighed in on URGN. Oppenheimer reissued an “outperform” rating and issued a $40.00 price target on shares of UroGen Pharma in a research note on Wednesday, October 16th. EF Hutton Acquisition Co. I upgraded shares of UroGen Pharma to a “strong-buy” rating in a report on Monday, October 14th. D. Boral Capital restated a “buy” rating and set a $25.00 price target on shares of UroGen Pharma in a report on Friday, December 6th. Finally, HC Wainwright reaffirmed a “buy” rating and issued a $60.00 price objective on shares of UroGen Pharma in a research note on Tuesday, October 15th. Five analysts have rated the stock with a buy rating and one has given a strong buy rating to the company. Based on data from MarketBeat.com, the company currently has an average rating of “Buy” and a consensus target price of $43.70.

About UroGen Pharma

UroGen Pharma Ltd., a biotechnology company, engages in the development and commercialization of solutions for urothelial and specialty cancers. It offers RTGel, a novel proprietary polymeric biocompatible, reverse thermal gelation hydrogel technology to improve therapeutic profiles of existing drugs; and Jelmyto for pyelocalyceal solution.